Therapeutic efficacy of [huCD64

× Id] BsAb against BCL₁ is dependent on CD4 and CD8 T cells. This figure represents a composite of 2 identical independent experiments. For each experiment, groups of 5 huCD64⁺, age-matched mice received 2 μg/d murine G-CSF subcutaneously 4 days before tumor inoculation and throughout the course of therapy (10 days in total). Mice were inoculated with 10⁵ BCL₁ tumor cells intraperitoneally on day 0 and were treated with twice-daily doses of 5 μg BsAb intraperitoneally on days 1 to 5 (50 μg/mouse in total). To deplete T cells, mice received either anti-CD8 (YTS169; 0.5 mg), anti-CD4 (GK1.5; 1 mg) or a mixture of both YTS169 (0.5 mg) and GK1.5 (1 mg) intraperitoneally 1 day before tumor and again on days 2 and 5 after the tumor inoculation. (The full treatment schedule is shown in the inset.) Treatments were as indicated: PBS (●), anti-CD4 + [huCD64 × Id] (▵), anti-CD8 + [huCD64 × Id] (▴), a mixture of anti-CD4 and anti-CD8 + [huCD64 × Id] (♦), control rat IgG + [huCD64 × Id] (○). Survival was recorded daily. Only cohorts treated without T-cell depletion and [huCD64 × Id] BsAb showed a significant increase in survival over all control groups (P ≤ .01).